TG Therapeutics reported stronger-than-expected Q3 2026 revenue and raised its full-year 2026 revenue guidance to over $1 billion. This positive financial update suggests strong operational performance and could lead to increased investor confidence.
TG Therapeutics announced third-quarter 2026 revenue of $259.9 million, exceeding consensus estimates, while EPS slightly missed. Crucially, the company raised its full-year revenue guidance, now expecting to surpass $1 billion. This indicates robust sales performance and positive momentum, particularly with anticipated strength in Q4. For traders, this is a significant positive catalyst in the short term, as the market typically rewards companies that beat revenue expectations and raise guidance. The long-term implication is a stronger financial outlook, potentially attracting more institutional investment. The key opportunity for traders is a potential upward movement in TGTX stock price following this positive news.